Current Report Filing (8-k)
February 05 2018 - 5:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 2, 2018
RELMADA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-184881
|
|
45-5401931
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
750
Third Avenue, 9
th
Floor
New
York, NY
|
|
10017
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
(212) 547-9591
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission
of Matters to a Vote of Security Holders.
On
February 2, 2018, Relmada Therapeutics, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Annual
Meeting”). Of the 12,057,858 shares of the Company’s common stock outstanding and eligible to vote at the Annual Meeting,
6,350,557 shares, or approximately 52.7% of the eligible common stock, were present either in person or by proxy. All
matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and the director nominee was
elected. The final results of the matters voted on at the Annual Meeting are provided below.
Proposal
1
: The following individual was elected as a Class III director to hold office for the term described below or until his resignation,
or respective successor is elected and qualified:
Director Name
|
|
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker
Non-Votes
|
|
Paul Kelly (Class III, 36 month term)
|
|
|
5,823,660
|
|
|
|
526,212
|
|
|
|
685
|
|
|
|
1,813,505
|
|
Proposal
2
: GBH CPAs, PC was ratified as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending
June 30, 2018.
For:
|
|
|
5,823,660
|
|
Against:
|
|
|
526,212
|
|
Abstained:
|
|
|
685
|
|
Proposal
3
: An amendment to the Company’s 2014 Stock Option and Equity Incentive Plan, as amended, to increase the number of
shares authorized to issue under the plan by 2.5 million shares was approved.
For:
|
|
|
3,120,503
|
|
Against:
|
|
|
1,391,038
|
|
Abstained:
|
|
|
25,511
|
|
Broker Non-Votes:
|
|
|
1,813,505
|
|
Proposal 4
: A non-binding vote on 2017 executive
compensation was approved.
For:
|
|
|
4,250,455
|
|
Against:
|
|
|
248,565
|
|
Abstained:
|
|
|
38,032
|
|
Broker Non-Votes:
|
|
|
1,813,505
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
February 5, 2018
|
RELMADA
THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/
Sergio Traversa
|
|
Name:
|
Sergio
Traversa
|
|
Title:
|
Chief
Executive Officer and
Interim Chief Financial Officer
|
2